Home
>
National Drug Code (NDC)
>
LUCENTIS
LUCENTIS - 50242-082-01 - (RANIBIZUMAB)
Drug Information of LUCENTIS
| Product NDC: | 50242-082 |
| Proprietary Name: | LUCENTIS |
| Non Proprietary Name: | RANIBIZUMAB |
| Active Ingredient(s): | 6 mg/mL & nbsp; RANIBIZUMAB |
| Administration Route(s): | INTRAVITREAL |
| Dosage Form(s): | INJECTION, SOLUTION |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of LUCENTIS
| Product NDC: | 50242-082 |
| Labeler Name: | Genentech, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | BLA125156 |
| Marketing Category: | BLA |
| Start Marketing Date: | 20120810 |
Package Information of LUCENTIS
| Package NDC: | 50242-082-01 |
| Package Description: | 1 VIAL, SINGLE-USE in 1 CARTON (50242-082-01) > .05 mL in 1 VIAL, SINGLE-USE |
NDC Information of LUCENTIS
| NDC Code | 50242-082-01 |
| Proprietary Name | LUCENTIS |
| Package Description | 1 VIAL, SINGLE-USE in 1 CARTON (50242-082-01) > .05 mL in 1 VIAL, SINGLE-USE |
| Product NDC | 50242-082 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | RANIBIZUMAB |
| Dosage Form Name | INJECTION, SOLUTION |
| Route Name | INTRAVITREAL |
| Start Marketing Date | 20120810 |
| Marketing Category Name | BLA |
| Labeler Name | Genentech, Inc. |
| Substance Name | RANIBIZUMAB |
| Strength Number | 6 |
| Strength Unit | mg/mL |
| Pharmaceutical Classes | Vascular Endothelial Growth Factor Receptor Inhibitors [MoA],Vascular Endothelial Growth Factor-directed Antibody [EPC],Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA] |
